Saredutant
Saredutant is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target substance-K receptor, substance-P receptor, and neuromedin-K receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | 8 | — | — | 8 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | 2 | — | — | 2 |
Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | SAREDUTANT |
INN | saredutant |
Description | Saredutant (SR-48,968) is a drug that acts as a NK2 receptor antagonist. It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.
|
Classification | Small molecule |
Drug class | tachykinin (neurokinin) receptor antagonists: NK2 receptor antagonists |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(=O)NC1(c2ccccc2)CCN(CC[C@H](CN(C)C(=O)c2ccccc2)c2ccc(Cl)c(Cl)c2)CC1 |
Identifiers
PDB | — |
CAS-ID | 142001-63-6 |
RxCUI | — |
ChEMBL ID | CHEMBL308148 |
ChEBI ID | — |
PubChem CID | 104974 |
DrugBank | DB06660 |
UNII ID | 720U2QK8I5 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
TACR2
TACR2
TACR1
TACR1
TACR3
TACR3
Organism
Homo sapiens
Gene name
TACR2
Gene synonyms
NK2R, NKNAR, TAC2R
NCBI Gene ID
Protein name
substance-K receptor
Protein synonyms
neurokinin 2 receptor, Neurokinin A receptor, neurokinin B receptor, NK-2 receptor, NK-2R, seven transmembrane helix receptor, Tachykinin receptor 2
Uniprot ID
Mouse ortholog
Tacr2 (21337)
substance-K receptor (P30549)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 48 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more